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Background: From 1988 to 1997 age-standardised total cancer mortality rates in the European Union (EU) fell
by around 9% in both sexes. Available cancer mortality data in Europe up to 2002 allow a first check of the
forecast of further declines in cancer mortality.
Patients and methods: We considered trends in age-standardised mortality from major cancer sites in the EU
during the period 1980–2002.
Results: For men, total cancer mortality, after a peak of 191.1/100 000 in 1987 declined to 177.8 in 1997 (7%), and
to 166.5 in 2002. Corresponding figures for females were 107.9/100 000, 100.5 and 95.2, corresponding to
falls of 7% from 1987 to 1997, and to 5% from 1997 to 2002. Over the last 5 years, lung cancer declined by 1.9%
per year in men, to reach 44.4/100 000, but increased by 1.7% in women, to reach 11.4. In 2002, for the first year,
lung cancer mortality in women was higher than that for intestinal cancer (11.1/100 000), and lung cancer became the
second site of cancer deaths in women after breast (17.9/100 000). From 1997 to 2002, appreciable declines
were observed in mortality from intestinal cancer in men (1.6% per year, to reach 18.8/100 000), and in women
(2.5%), as well as for breast (1.7% per year) and prostate cancer (1.4%).
Conclusions: Despite the persisting rises in female lung cancer, the recent trends in cancer mortality in the EU are
encouraging and indicate that an 11% reduction in total cancer mortality from 2000 to 2015 is realistic and possible.
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introduction
Cancer mortality in the European Union (EU), as in North
America, has peaked in the late 1980s [1, 2]. From 1988 to 1997
age-standardised total cancer mortality rates felt by 9.3% in men
and 8.8% in women. This corresponded to the avoidance of
80 000 deaths per year in the late 1990s in the 15 countries of the
formerEU, as comparedwith cancermortality in the late 1980s [2].
On the basis of the recent trends in cancer mortality in the
25 countries of the EU, a forecast was proposed for cancer
mortality in 2015 of a further fall by 11% in cancer deaths from
2000 to 2015, corresponding to >150 000 fewer deaths per year
in 2015 as compared with the rates of 2000 [3].
Data have now been made available for cancer mortality in
Europe up to 2002, allowing a first check of the forecast of
further declines in cancer mortality.
patients and methods
We obtained official death certification numbers and population estimates
for 24 countries of the EU, except Cyprus, from the World Health
Organization database during the period 1980–2002. We recoded all cancer
deaths according to the 10th Revision of the International Classification of
Diseases, and pooled together all intestinal sites, including rectum, and
all uterine cancers (cervix and endometrium). From the matrices of
certified deaths and resident populations we computed age-specific rates
for each 5-year age group and calendar period, as well as age-standardised
rates on the world standard population.
results
Table 1 gives overall age-standardised mortality from all cancers,
lung, intestinal, breast and prostate cancers during the period
1980–2002, and the annual percent change in rate between the
peak of 1985–1989 and 1997, and in the subsequent period
1997–2002.
In men, total cancer mortality declined by 7% from
191.1/100 000 around 1987 to 177.8/100 000 around 1997, and
by a further 6% to 166.5 in 2002. Corresponding figures for
females were 107.9/100 000, 100.5 and 95.2/100 000,
corresponding to falls of 7% from 1987 to 1997, and of 5% from
1997 to 2002. Lung cancer in men declined from 55.0/100 000
around 1987 to 49.2 around 1997 (11%), and to 44.4 (10%)
in 2002. In women, lung cancer mortality was 9.1/100 000
around 1987, 10.6/100 000 (+16%) around 1997 and 11.4 (+8%)
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in 2002. Intestinal cancer declined by 10% in women from 1987
to 1997, and by 6% in men and 12% in women from 1997 to
2002. Breast cancer mortality declined from 21.5/100 000
around 1987 to 19.8 around 1997 (8%) to 17.9/100 000
(10%) in 2002. Prostate cancer was approximately stable until
the early 1990s, but declined from 15.3 around 1992 to 13.9
(9%) in 2002.
Figure 1 gives trends in mortality from the eight major cancer
sites in EU men and women during the period 1980–2002.
Besides the trends previously described, steady persistent falls
Table 1. Age-standardised mortality rates per 100 000 (world standard population) from all cancers, lung, intestinal, breast and prostate cancers by
gender in the European Union, 1982–2002
All cancers Lung Intestines Breast Prostate
Males Females Males Females Males Females Females Males
Year
1982a 187.0 108.3 53.2 8.1 19.7 14.3 20.7 13.8
1987a 191.1 107.9 55.0 9.1 20.2 14.0 21.5 14.9
1992a 187.8 105.5 53.4 9.9 20.5 13.5 21.2 15.3
1997a 177.8 100.5 49.2 10.6 20.1 12.6 19.8 15.1
2002 166.5 95.2 44.4 11.4 18.8 11.1 17.9 13.9
Change in rate, 1987–1997
Absolute 13.3 7.4 5.8 +1.5 0.1 1.4 0.7 +0.2
Percent 7.0 6.9 10.5 +16.5 0.5 10.0 7.9 +1.3
Annual %b 0.78 0.74 1.16 +1.36 0.15 1.08 0.80 +0.14
Change in rate, 1997–2002
Absolute 11.3 5.3 4.8 +0.8 1.3 1.5 1.9 1.2
Percent 6.4 5.3 9.8 +7.5 6.5 11.9 9.6 7.9
Annual %b 1.22 1.04 1.91 +1.65 1.60 2.52 1.72 1.41
aAverage annual rate in quinquennial periods 1980–1984, 1985–1989, 1990–1994 and 1995–1999.
bFrom a log-linear model based on single calendar year rates.
Figure 1. A and B. Trends in age-standardised (per 100 000, world population) mortality rates for cancers by sex in the 25 countries (except Cyprus) of the
European Union, 1980–2002. Countries are: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland,
Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and United Kingdom.
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were observed for stomach cancer in both sexes, although
stomach cancer is still the fifth cause of death in both sexes
combined in the EU, as well as uterine (cervix) in women.
Moderate declines were observed over recent years for
leukaemias in both sexes, oral cavity, pharynx and oesophagus
in men and ovary in women. The only major site showing
persisting rise over the last two decades was lung cancer in
women whose rate in 2002 (11.4/100 000) was for the first year
higher than that for intestinal cancer (11.1/100 000). Thus, lung
cancer is now the second site of cancer deaths in European
women following breast (17.9/100 000), and the annual rate of
increase has been larger over the last 5 years (+1.85%) as
compared with the previous decade (+1.36%).
discussion
Despite the persisting rises in female lung cancer due to spread
of tobacco smoking among European women after the second
World War, and mainly since the early 1970s [4, 5], the recent
trends in cancer mortality in the EU remain favourable, with
a >5% fall in both sexes over the last 5 years. In men, about 40%
of the decline is due to lung cancer alone, and at least an
additional 10% to other tobacco-related cancers, following the
decreased prevalence of tobacco smoking in European men over
the last decades [4]. About 15% of the fall is still due to the
persisting decline of gastric cancer, and other relevant
contributions are due to recent falls in colorectal and prostate
cancers.
In women, the largest contributions to the fall in cancer
mortality are due to breast and colorectum, indicating that the
advancements are largely attributable to improved diagnosis,
and mostly treatment of breast cancer [6–8].
The most recent trends in cancer mortality in Europe are
thus encouraging and indicate that the forecast of 11%
reduction in cancer mortality from 2000 to 2015 is realistic and
possible. In fact, a linear extrapolation of a fall by 1.13% per year
would correspond to a 16% decrease over a 15-year period. In
terms of total numbers of cancer deaths, this would correspond
to 1.2 million deaths in 2015 in the EU, as compared with
about 1.1 million in 2002, and to 1.4 million in 2015 in the
absence of continuing falls in rates.
Further control of tobacco, and consequently of tobacco-
related cancer mortality, remains a priority not only for men
but also for women. Widespread and uniform adoption across
Europe of advanced screening diagnostic and therapeutic
approaches is also urgent to reduce the burden of cancer
mortality in the EU [9, 10].
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